The global Menopausal Hormone Therapy market size is predicted to grow from US$ 27320 million in 2025 to US$ 39480 million in 2031; it is expected to grow at a CAGR of 6.3% from 2025 to 2031.
Menopausal hormone therapy (MHT) is a treatment that uses hormones to relieve the symptoms of menopause. Menopause is a natural process that occurs when a woman"s ovaries stop producing estrogen and progesterone. This can cause a variety of symptoms, including hot flashes, night sweats, vaginal dryness, mood swings, and difficulty sleeping.
The menopausal hormone therapy (MHT) market is expected to grow significantly in the coming years, driven by a number of factors, including:
Rising awareness of the benefits of menopausal hormone therapy: There is a growing awareness of the benefits of menopausal hormone therapy, such as relief of menopausal symptoms, reduced risk of osteoporosis, and improved cardiovascular health. This is also driving the demand for menopausal hormone therapy.
Changing social norms: Social norms are changing around menopause, and women are becoming more open to discussing their symptoms and seeking treatment. This is also driving the demand for menopausal hormone therapy.
The North American region is expected to be the largest market for menopausal hormone therapy, followed by Europe and the Asia Pacific region. The growth of the market in the North American region is being driven by the high prevalence of menopause and the easy availability of menopausal hormone therapy products.
Overall, the menopausal hormone therapy market is expected to grow significantly in the coming years, driven by increasing population of menopausal women, rising awareness of the benefits of menopausal hormone therapy, and changing social norms.
The 鈥淢enopausal Hormone Therapy Industry Forecast鈥� looks at past sales and reviews total world Menopausal Hormone Therapy sales in 2024, providing a comprehensive analysis by region and market sector of projected Menopausal Hormone Therapy sales for 2025 through 2031. With Menopausal Hormone Therapy sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Menopausal Hormone Therapy industry.
This Insight Report provides a comprehensive analysis of the global Menopausal Hormone Therapy landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Menopausal Hormone Therapy portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms鈥� unique position in an accelerating global Menopausal Hormone Therapy market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Menopausal Hormone Therapy and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Menopausal Hormone Therapy.
This report presents a comprehensive overview, market shares, and growth opportunities of Menopausal Hormone Therapy market by product type, application, key players and key regions and countries.
Segmentation by Type:
Estrogen
Progesterone
Segmentation by Application:
Hospital
Clinic
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Eli Lilly
Pfizer
AbbVie
Novo Nordisk
Merck KGaA
Mylan
Bayer
Teva
Novartis
Abbott
Roche
Endo International
Ipsen
ANI Pharmaceuticals
TherapeuticsMD
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Scope of the Report
1.1 麻豆原创 Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 麻豆原创 Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 麻豆原创 Estimation Caveats
2 Executive Summary
2.1 World 麻豆原创 Overview
2.1.1 Global Menopausal Hormone Therapy 麻豆原创 Size (2020-2031)
2.1.2 Menopausal Hormone Therapy 麻豆原创 Size CAGR by Region (2020 VS 2024 VS 2031)
2.1.3 World Current & Future Analysis for Menopausal Hormone Therapy by Country/Region (2020, 2024 & 2031)
2.2 Menopausal Hormone Therapy Segment by Type
2.2.1 Estrogen
2.2.2 Progesterone
2.3 Menopausal Hormone Therapy 麻豆原创 Size by Type
2.3.1 Menopausal Hormone Therapy 麻豆原创 Size CAGR by Type (2020 VS 2024 VS 2031)
2.3.2 Global Menopausal Hormone Therapy 麻豆原创 Size 麻豆原创 Share by Type (2020-2025)
2.4 Menopausal Hormone Therapy Segment by Application
2.4.1 Hospital
2.4.2 Clinic
2.4.3 Others
2.5 Menopausal Hormone Therapy 麻豆原创 Size by Application
2.5.1 Menopausal Hormone Therapy 麻豆原创 Size CAGR by Application (2020 VS 2024 VS 2031)
2.5.2 Global Menopausal Hormone Therapy 麻豆原创 Size 麻豆原创 Share by Application (2020-2025)
3 Menopausal Hormone Therapy 麻豆原创 Size by Player
3.1 Menopausal Hormone Therapy 麻豆原创 Size 麻豆原创 Share by Player
3.1.1 Global Menopausal Hormone Therapy Revenue by Player (2020-2025)
3.1.2 Global Menopausal Hormone Therapy Revenue 麻豆原创 Share by Player (2020-2025)
3.2 Global Menopausal Hormone Therapy Key Players Head office and Products Offered
3.3 麻豆原创 Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 Menopausal Hormone Therapy by Region
4.1 Menopausal Hormone Therapy 麻豆原创 Size by Region (2020-2025)
4.2 Global Menopausal Hormone Therapy Annual Revenue by Country/Region (2020-2025)
4.3 Americas Menopausal Hormone Therapy 麻豆原创 Size Growth (2020-2025)
4.4 APAC Menopausal Hormone Therapy 麻豆原创 Size Growth (2020-2025)
4.5 Europe Menopausal Hormone Therapy 麻豆原创 Size Growth (2020-2025)
4.6 Middle East & Africa Menopausal Hormone Therapy 麻豆原创 Size Growth (2020-2025)
5 Americas
5.1 Americas Menopausal Hormone Therapy 麻豆原创 Size by Country (2020-2025)
5.2 Americas Menopausal Hormone Therapy 麻豆原创 Size by Type (2020-2025)
5.3 Americas Menopausal Hormone Therapy 麻豆原创 Size by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Menopausal Hormone Therapy 麻豆原创 Size by Region (2020-2025)
6.2 APAC Menopausal Hormone Therapy 麻豆原创 Size by Type (2020-2025)
6.3 APAC Menopausal Hormone Therapy 麻豆原创 Size by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe Menopausal Hormone Therapy 麻豆原创 Size by Country (2020-2025)
7.2 Europe Menopausal Hormone Therapy 麻豆原创 Size by Type (2020-2025)
7.3 Europe Menopausal Hormone Therapy 麻豆原创 Size by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Menopausal Hormone Therapy by Region (2020-2025)
8.2 Middle East & Africa Menopausal Hormone Therapy 麻豆原创 Size by Type (2020-2025)
8.3 Middle East & Africa Menopausal Hormone Therapy 麻豆原创 Size by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 麻豆原创 Drivers, Challenges and Trends
9.1 麻豆原创 Drivers & Growth Opportunities
9.2 麻豆原创 Challenges & Risks
9.3 Industry Trends
10 Global Menopausal Hormone Therapy 麻豆原创 Forecast
10.1 Global Menopausal Hormone Therapy Forecast by Region (2026-2031)
10.1.1 Global Menopausal Hormone Therapy Forecast by Region (2026-2031)
10.1.2 Americas Menopausal Hormone Therapy Forecast
10.1.3 APAC Menopausal Hormone Therapy Forecast
10.1.4 Europe Menopausal Hormone Therapy Forecast
10.1.5 Middle East & Africa Menopausal Hormone Therapy Forecast
10.2 Americas Menopausal Hormone Therapy Forecast by Country (2026-2031)
10.2.1 United States 麻豆原创 Menopausal Hormone Therapy Forecast
10.2.2 Canada 麻豆原创 Menopausal Hormone Therapy Forecast
10.2.3 Mexico 麻豆原创 Menopausal Hormone Therapy Forecast
10.2.4 Brazil 麻豆原创 Menopausal Hormone Therapy Forecast
10.3 APAC Menopausal Hormone Therapy Forecast by Region (2026-2031)
10.3.1 China Menopausal Hormone Therapy 麻豆原创 Forecast
10.3.2 Japan 麻豆原创 Menopausal Hormone Therapy Forecast
10.3.3 Korea 麻豆原创 Menopausal Hormone Therapy Forecast
10.3.4 Southeast Asia 麻豆原创 Menopausal Hormone Therapy Forecast
10.3.5 India 麻豆原创 Menopausal Hormone Therapy Forecast
10.3.6 Australia 麻豆原创 Menopausal Hormone Therapy Forecast
10.4 Europe Menopausal Hormone Therapy Forecast by Country (2026-2031)
10.4.1 Germany 麻豆原创 Menopausal Hormone Therapy Forecast
10.4.2 France 麻豆原创 Menopausal Hormone Therapy Forecast
10.4.3 UK 麻豆原创 Menopausal Hormone Therapy Forecast
10.4.4 Italy 麻豆原创 Menopausal Hormone Therapy Forecast
10.4.5 Russia 麻豆原创 Menopausal Hormone Therapy Forecast
10.5 Middle East & Africa Menopausal Hormone Therapy Forecast by Region (2026-2031)
10.5.1 Egypt 麻豆原创 Menopausal Hormone Therapy Forecast
10.5.2 South Africa 麻豆原创 Menopausal Hormone Therapy Forecast
10.5.3 Israel 麻豆原创 Menopausal Hormone Therapy Forecast
10.5.4 Turkey 麻豆原创 Menopausal Hormone Therapy Forecast
10.6 Global Menopausal Hormone Therapy Forecast by Type (2026-2031)
10.7 Global Menopausal Hormone Therapy Forecast by Application (2026-2031)
10.7.1 GCC Countries 麻豆原创 Menopausal Hormone Therapy Forecast
11 Key Players Analysis
11.1 Eli Lilly
11.1.1 Eli Lilly Company Information
11.1.2 Eli Lilly Menopausal Hormone Therapy Product Offered
11.1.3 Eli Lilly Menopausal Hormone Therapy Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.1.4 Eli Lilly Main Business Overview
11.1.5 Eli Lilly Latest Developments
11.2 Pfizer
11.2.1 Pfizer Company Information
11.2.2 Pfizer Menopausal Hormone Therapy Product Offered
11.2.3 Pfizer Menopausal Hormone Therapy Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.2.4 Pfizer Main Business Overview
11.2.5 Pfizer Latest Developments
11.3 AbbVie
11.3.1 AbbVie Company Information
11.3.2 AbbVie Menopausal Hormone Therapy Product Offered
11.3.3 AbbVie Menopausal Hormone Therapy Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.3.4 AbbVie Main Business Overview
11.3.5 AbbVie Latest Developments
11.4 Novo Nordisk
11.4.1 Novo Nordisk Company Information
11.4.2 Novo Nordisk Menopausal Hormone Therapy Product Offered
11.4.3 Novo Nordisk Menopausal Hormone Therapy Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.4.4 Novo Nordisk Main Business Overview
11.4.5 Novo Nordisk Latest Developments
11.5 Merck KGaA
11.5.1 Merck KGaA Company Information
11.5.2 Merck KGaA Menopausal Hormone Therapy Product Offered
11.5.3 Merck KGaA Menopausal Hormone Therapy Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.5.4 Merck KGaA Main Business Overview
11.5.5 Merck KGaA Latest Developments
11.6 Mylan
11.6.1 Mylan Company Information
11.6.2 Mylan Menopausal Hormone Therapy Product Offered
11.6.3 Mylan Menopausal Hormone Therapy Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.6.4 Mylan Main Business Overview
11.6.5 Mylan Latest Developments
11.7 Bayer
11.7.1 Bayer Company Information
11.7.2 Bayer Menopausal Hormone Therapy Product Offered
11.7.3 Bayer Menopausal Hormone Therapy Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.7.4 Bayer Main Business Overview
11.7.5 Bayer Latest Developments
11.8 Teva
11.8.1 Teva Company Information
11.8.2 Teva Menopausal Hormone Therapy Product Offered
11.8.3 Teva Menopausal Hormone Therapy Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.8.4 Teva Main Business Overview
11.8.5 Teva Latest Developments
11.9 Novartis
11.9.1 Novartis Company Information
11.9.2 Novartis Menopausal Hormone Therapy Product Offered
11.9.3 Novartis Menopausal Hormone Therapy Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.9.4 Novartis Main Business Overview
11.9.5 Novartis Latest Developments
11.10 Abbott
11.10.1 Abbott Company Information
11.10.2 Abbott Menopausal Hormone Therapy Product Offered
11.10.3 Abbott Menopausal Hormone Therapy Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.10.4 Abbott Main Business Overview
11.10.5 Abbott Latest Developments
11.11 Roche
11.11.1 Roche Company Information
11.11.2 Roche Menopausal Hormone Therapy Product Offered
11.11.3 Roche Menopausal Hormone Therapy Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.11.4 Roche Main Business Overview
11.11.5 Roche Latest Developments
11.12 Endo International
11.12.1 Endo International Company Information
11.12.2 Endo International Menopausal Hormone Therapy Product Offered
11.12.3 Endo International Menopausal Hormone Therapy Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.12.4 Endo International Main Business Overview
11.12.5 Endo International Latest Developments
11.13 Ipsen
11.13.1 Ipsen Company Information
11.13.2 Ipsen Menopausal Hormone Therapy Product Offered
11.13.3 Ipsen Menopausal Hormone Therapy Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.13.4 Ipsen Main Business Overview
11.13.5 Ipsen Latest Developments
11.14 ANI Pharmaceuticals
11.14.1 ANI Pharmaceuticals Company Information
11.14.2 ANI Pharmaceuticals Menopausal Hormone Therapy Product Offered
11.14.3 ANI Pharmaceuticals Menopausal Hormone Therapy Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.14.4 ANI Pharmaceuticals Main Business Overview
11.14.5 ANI Pharmaceuticals Latest Developments
11.15 TherapeuticsMD
11.15.1 TherapeuticsMD Company Information
11.15.2 TherapeuticsMD Menopausal Hormone Therapy Product Offered
11.15.3 TherapeuticsMD Menopausal Hormone Therapy Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.15.4 TherapeuticsMD Main Business Overview
11.15.5 TherapeuticsMD Latest Developments
12 Research Findings and Conclusion
听
听
*If Applicable.
